title: [Recombinant monoclonal antibodies for the treatment and prevention of viral infections].
abstract: Recombinant monoclonal antibodies (mAB) are a new class of medicinal preparations with the potential for wide application to the treatment of viral infections. Marked progress in the development of therapeutic mAB against respiratory syncytial influenza A viruses, West Nile virus, and some others has been achieved in recent years in contrast to HIV and hepatitis C pathogens. The main obstacle hampering this work is great heterogeneity and diversity of these viruses. Gene engineering technologies make it possible to modify mAB, modulate their efficacy, and create bi-specific mAB. This review presents data on the development and prospects for the application of mAB to prevent and treat viral infections.
authors.forename: S V
authors.initials: SV
authors.lastname: Al'khovskiĭ
mesh_terms: D000911:Antibodies, Monoclonal / Q000096:biosynthesis / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D003140:Communicable Disease Control; D006678:HIV / Q000187:drug effects / Q000276:immunology*; D016174:Hepacivirus / Q000187:drug effects / Q000276:immunology*; D006801:Humans; D007155:Immunologic Factors / Q000096:biosynthesis / Q000627:therapeutic use; D015202:Protein Engineering; D011994:Recombinant Proteins / Q000096:biosynthesis / Q000627:therapeutic use; D012136:Respiratory Syncytial Viruses / Q000187:drug effects / Q000276:immunology*; D014777:Virus Diseases / Q000276:immunology / Q000628:therapy / Q000821:virology; D014902:West Nile virus / Q000187:drug effects / Q000276:immunology*
chemical_list: D000911:Antibodies, Monoclonal; D007155:Immunologic Factors; D011994:Recombinant Proteins